Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Rustgi VK, Lee WM, Lawitz E, Gordon SC, Afdhal N, Poordad F, Bonkovsky HL, Bengtsson L, Chandorkar G, Harding M, McNair L, Aalyson M, Alam J, Kauffman R, Gharakhanian S, McHutchison JG; MErimepodib TRiple cOmbination Study Group. Rustgi VK, et al. Hepatology. 2009 Dec;50(6):1719-26. doi: 10.1002/hep.23204. Hepatology. 2009. PMID: 19852040 Clinical Trial.
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks.
Sherman M, Yurdaydin C, Simsek H, Silva M, Liaw YF, Rustgi VK, Sette H, Tsai N, Tenney DJ, Vaughan J, Kreter B, Hindes R; AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group. Sherman M, et al. Among authors: rustgi vk. Hepatology. 2008 Jul;48(1):99-108. doi: 10.1002/hep.22323. Hepatology. 2008. PMID: 18537189 Clinical Trial.
Future trends in hepatology: challenges and opportunities.
Rustgi VK, Davis GL, Herrine SK, McCullough AJ, Friedman SL, Gores GJ. Rustgi VK, et al. Hepatology. 2008 Aug;48(2):655-61. doi: 10.1002/hep.22451. Hepatology. 2008. PMID: 18666245 No abstract available.
Racial differences in hepatitis C treatment eligibility.
Melia MT, Muir AJ, McCone J, Shiffman ML, King JW, Herrine SK, Galler GW, Bloomer JR, Nunes FA, Brown KA, Mullen KD, Ravendhran N, Ghalib RH, Boparai N, Jiang R, Noviello S, Brass CA, Albrecht JK, McHutchison JG, Sulkowski MS; IDEAL Study Team. Melia MT, et al. Hepatology. 2011 Jul;54(1):70-8. doi: 10.1002/hep.24358. Hepatology. 2011. PMID: 21488082 Free PMC article.
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.
Nelson DR, Zeuzem S, Andreone P, Ferenci P, Herring R, Jensen DM, Marcellin P, Pockros PJ, Rodríguez-Torres M, Rossaro L, Rustgi VK, Sepe T, Sulkowski M, Thomason IR, Yoshida EM, Chan A, Hill G. Nelson DR, et al. Among authors: rustgi vk. Ann Hepatol. 2012 Jan-Feb;11(1):15-31. Ann Hepatol. 2012. PMID: 22166557 Free PMC article. Clinical Trial.
152 results